AMENDMENTS TO THE CLAIMS

Please amend claims 1-26, 30, 32 and 33 and add new claim 34. Please cancel claims 27-29 without prejudice or disclaimer. Deletions appear in ~~strikethrough font~~, and additions are underlined. This listing of claims below will replace all prior versions and listings of claims in the application.

Complete listing of claims

1. (Currently amended) A compound of formula (I):



(I)

wherein

B ~~is~~ represents a group chosen from ~~a~~ phenyl, naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, ~~or~~ biphenyl ~~group,~~ ~~or~~ and a 5 to 10-membered heteroaromatic group containing one or more heteroatoms ~~selected~~ chosen from N, O ~~or~~ and S;

R^1, R^2 and R^3 each independently represent a group chosen from a hydrogen atom, ~~or~~ a halogen atom, ~~or a~~ hydroxy, phenyl, $-OR^5$, $-SR^5$, $-NR^5R^6$, $-NHCOR^5$, $-CONR^5R^6$, -CN, $-NO_2$, $-COOR^5$, ~~or~~ $-CF_3$ ~~group~~, ~~or~~ a straight optionally substituted lower alkyl group, ~~or~~ and a branched, optionally substituted lower alkyl group;

or R^1 and R^2 together form an aromatic or alicyclic ring or a heterocyclic group;

R^5 and R^6 each independently represent a group chosen from a hydrogen atom, a straight optionally substituted lower alkyl group ~~or~~ and a branched, optionally substituted lower alkyl group, or R^5 and R^6 together form an alicyclic ring;

n is an integer from 0 to 4;

A represents a group chosen ~~selected~~ from $-CH_2-$, $-CH=CR^7-$, $-CR^7=CH-$, $-CR^7R^8-$, -CO-, -O-, -S-, -S(O)-, $-S(O)_2-$ and $-NR^7-$, wherein R^7 and R^8 each independently represent a group chosen from hydrogen atom, a straight optionally substituted lower alkyl group ~~or~~ and a branched, optionally substituted lower alkyl group, or R^7 and R^8 together form an alicyclic ring;

m is an integer from 0 to 8;

R^4 represents a lower alkyl group;

D represents a group of formula i) or ii)

i)



ii)



wherein

R^9 represents a group chosen ~~selected~~ from phenyl, 2-furyl, 3-furyl, 2-thienyl ~~or~~ and 3-thienyl;

R^{10} represents a group chosen ~~selected~~ from phenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl ~~or~~ and C_3-C_7 cycloalkyl;

and R^{11} represents a group chosen from a hydrogen atom, ~~or a~~ hydroxy, methyl, ~~or~~ and CH_2OH ~~group~~;

wherein each of the cyclic groups represented by R^9 and R^{10} ~~being~~ is independently optionally substituted by one or two substituents chosen ~~selected~~ from halogen, straight optionally substituted lower alkyl, ~~or~~ branched, optionally substituted lower alkyl, hydroxy, optionally substituted lower alkoxy, nitro, cyano, $-CO_2R^{12}$ ~~or~~ and $-NR^{12}R^{13}$, wherein R^{12} and R^{13} are identical or different and are each independently chosen~~selected~~ from a hydrogen atom, ~~and~~ straight optionally substituted lower alkyl groups ~~or~~ and branched, optionally substituted lower alkyl groups;

Q represents a single bond or a group chosen from $-CH_2-$, $-CH_2-CH_2-$, -O-, $-O-CH_2-$, -S-, $-S-CH_2-$ ~~or~~ and -CH=CH- ~~group~~;

X^- represents a pharmaceutically acceptable anion of a mono or polyvalent acid;

~~including all~~ or an individual stereoisomer~~s~~ of a compound of formula (I) or ~~and~~ a mixture~~s~~ of stereoisomers of a compound of formula (I) ~~thereof~~;

with the proviso that in those compounds of formula (I) wherein B is phenyl, R^9 is unsubstituted phenyl, R^{10} is unsubstitued phenyl or unsubstituted C_3-C_7 cycloalkyl, and R^{11} is hydrogen or hydroxy, the sequence $-(CH_2)_n-A-(CH_2)_m-$ is not one of methylene, ethylene or propylene.

2. (Currently amended) A compound according to claim 1, wherein B represents a group chosen from phenyl, pyrrolyl, thienyl, furyl, biphenyl, naphthalenyl, 5, 6, 7,

8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, imidazolyl ~~or~~ and benzothiazolyl-~~group~~.

3. (Currently amended) A compound according to claim 2, wherein B represents a group chosen from phenyl, thienyl ~~or~~ and pyrrolyl ~~group~~.

4. (Currently amended) A compound according to claim 1, ~~any one of the preceding claims~~ wherein R^1, R^2 and R^3 each independently represents a group chosen from a hydrogen atom, ~~or~~ a halogen atom, ~~or~~ a hydroxy, methyl, tert-butyl, -CH_2OH, 3-hydroxypropyl, -OMe, -NMe_2, -NHCOMe, -$CONH_2$, -CN, -NO_2, -COOMe ~~or~~ and -CF_3 ~~group~~.

5. (Currently amended) A compound according to claim 4, wherein R^1, R^2 and R^3 each independently represents a group chosen from hydrogen, fluorine, chlorine ~~or~~ and hydroxy.

6. (Currently amended) A compound according to claim 1, ~~any one of the preceding claims~~ wherein n = 0 or 1; m is an integer from 1 to 6; and A represents a group chosen from -CH_2-, -CH=CH-, -CO-, -NMe-, -O- ~~or~~ and -S- ~~group~~.

7. (Currently amended) A compound according to claim 6, wherein A is a group chosen from -CH_2-, -CH=CH- ~~or~~ and -O- ~~group~~.

8. (Currently amended) A compound according to claim 6, wherein the pyrrolidinium group is substituted on the nitrogen atom with a C_1-C_4 alkyl group and another group chosen ~~selected~~ from 3-phenoxypropyl, 2-phenoxyethyl, 3-phenylallyl, phenethyl, 3-phenylpropyl, 3-(3-hydroxyphenoxy)propyl, 3-(4-fluorophenoxy)propyl, 3-thien-2-ylpropyl, 4-oxo-4-thien-2-ylbutyl, 2-benzyloxyethyl, 3-o-tolyloxypropyl, 3-(3-cyanophenoxy)propyl, 3-(methylphenylamino)propyl, 3-phenylsulphanylpropyl, 4-oxo-4-phenylbutyl, 4-(4-

fluorophenyl)-4-oxobutyl, 3-(2-chlorophenoxy)propyl, 3-(2,4-difluorophenoxy)propyl, 3-(4-methoxyphenoxy)propyl, and 3-(benzo[1,3]dioxol-5-yloxy)propyl.

9. (Currently amended) A compound according to claim 8 wherein the pyrrolidinium group is substituted on the nitrogen atom with a C_1-C_4 alkyl group and another group chosen ~~selected~~ from 3-phenoxypropyl, 2-phenoxyethyl, 3-phenylallyl, phenethyl, 3-phenylpropyl, 3-(3-hydroxyphenoxy)propyl, 3-(4-fluorophenoxy)propyl, 4-(4-fluorophenyl)-4-oxobutyl ~~or~~ and 3-thien-2-ylpropyl.

10. (Currently amended) A compound according to claim 1, ~~any one of the preceding claims~~ wherein D is a group of formula i), and wherein R^9 is a group chosen ~~selected~~ from phenyl, 2-thienyl ~~or~~ and 2-furyl; R^{10} is a group chosen ~~selected~~ from phenyl, 2-thienyl, cyclohexyl ~~or~~ and cyclopentyl; and R^{11} is a hydroxy group.

11. (Currently amended) A compound according to claim 1, ~~any one of claims 1 to 9~~ wherein D is a group of formula ii), and wherein Q is a single bond or an oxygen atom and R^{11} is a hydrogen atom or a hydroxy group.

12. (Currently amended) A compound according to claim 1, ~~any one of the preceding claims~~ wherein X^- is chosen from chloride, bromide, trifluoroacetate ~~or~~ and methanesulphonate.

13. (Currently amended) A compound according to claim 1, ~~any one of the preceding claims~~ wherein the carbon at the 3-position of the pyrrolidinium ring has a R configuration.

14. (Currently amended) A compound according to claim 1, ~~any one of claims 1 to 12~~ wherein the carbon at the 3-position of the pyrrolidinium ring has a S configuration.

15. (Currently amended) A compound according to claim 1, ~~any one of claims 1 to 10 and 12 to 14~~ wherein D is a group of formula i) and the carbon substituted by R^9, R^{10} and R^{11} has a R configuration.

16. (Currently amended) A compound according to claim 1, ~~any one of claims 1 to 10 and 12 to 14~~ wherein D is a group of formula i) and the carbon substituted by R^9, R^{10} and R^{11} has a S configuration.

17. (Currently amended) A compound according to claim 1, ~~any one of the preceding claims~~, ~~which~~ wherein said compound is a single isomer.

18. (Currently amended) A compound according to claim 1 ~~which is one of~~ chosen from:

3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-phenethylpyrrolidinium trifluoroacetate;

3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide;

3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-thien-2-ylpropyl)pyrrolidinium bromide;

3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenoxypropyl) pyrrolidinium bromide;

3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(-3-phenylallyl)pyrrolidinium trifluoroacetate;

3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(4-oxo-4-thien-2-ylbutyl)pyrrolidinium trifluoroacetate;

1-[4-(4-Fluorophenyl)-4-oxobutyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-methylpyrrolidinium trifluoroacetate;

1-Ethyl-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(3-hydroxyphenoxy)propyl]pyrrolidinium trifluoroacetate;

3-(2-Hydroxy-2,2-dithien-2-yl-acetoxy)-1-methyl-1-(3-pyrrol-1-ylpropyl)pyrrolidinium trifluoroacetate;

3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-[6-(4-phenylbutoxy)hexyl]pyrrolidinium trifluoroacetate;

1-(2-Benzyloxyethyl)-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methylpyrrolidinium trifluoroacetate;

1-[3-(3-Cyanophenoxy)propyl]-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methylpyrrolidinium trifluoroacetate;

3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methyl-1-[3-(naphthalen-1-yloxy)propyl]pyrrolidinium trifluoroacetate;

3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methyl-1-[3-(methylphenylamino)propyl]pyrrolidinium trifluoroacetate;

3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-ethyl-1-(3-phenylsulphanylpropyl)pyrrolidinium trifluoroacetate;

1-[3-(Benzothiazol-2-yloxy)propyl]-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methylpyrrolidinium trifluoroacetate;

3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;

3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methyl-1-[3-(2,4,6-trimethylphenoxy)propyl]pyrrolidinium trifluoroacetate;

1-[3-(2-Chlorophenoxy)propyl]-3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methylpyrrolidinium trifluoroacetate;

3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methyl-1-[3-(3-trifluoromethylphenoxy)propyl]pyrrolidinium trifluoroacetate;

1-[3-(Biphenyl-4-yloxy)propyl]-3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methylpyrrolidinium trifluoroacetate;

3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-[3-(2,4-difluorophenoxy)propyl]-1-methylpyrrolidinium trifluoroacetate;

3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-ethyl-1-[3-(4-methoxyphenoxy)propyl]-pyrrolidinium trifluoroacetate;

3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methyl-1-[3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propyl]pyrrolidinium trifluoroacetate;
3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methyl-1-[3-(1-methyl-1H-imidazol-2-ylsulphanyl)propyl]pyrrolidinium trifluoroacetate;
1-Methyl-1-phenethyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium bromide;
1-Methyl-1-(3-phenoxypropyl)-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium bromide;
1-[3-(Benzo[1,3]dioxol-5-yloxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;
1-[3-(2-Carbamoylphenoxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;
1-[3-(3-Dimethylaminophenoxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;
1-[3-(4-Acetylaminophenoxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;
1-[3-(4-Methoxycarbonylphenoxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;
1-Methyl-1-[3-(4-nitrophenoxy)propyl]-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;
1-[3-(4-Hydroxymethylphenoxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;
3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(3-hydroxyphenoxy)propyl]-1-methylpyrrolidinium formate;
1-[3-(4-Fluorophenoxy)propyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-methylpyrrolidinium chloride;
3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenylpropyl)pyrrolidinium bromide;
1-Methyl-1-(3-o-tolyloxypropyl)-3-[(9H-xanthen-9-ylcarbonyl)oxy]pyrrolidinium bromide;

3-{[(9-hydroxy-9H-fluoren-9-yl)carbonyl]oxy}-1-methyl-1-(4-oxo-4-phenylbutyl)pyrrolidinium formate; and
3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-ethyl-1-(3-phenylsulfanylpropyl)pyrrolidinium bromide.

19. (Currently amended) A compound according to claim 1 ~~which is one of~~chosen from:
(3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-phenethylpyrrolidinium bromide;
(3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-phenethylpyrrolidinium bromide;
(3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide;
(3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide;
(3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-thien-2-ylpropyl)pyrrolidinium bromide;
(3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;
(3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;
(3R)-3-[(2R)-2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy]-1-ethyl-1-(3-phenylsulphanylpropyl)pyrrolidinium trifluoroacetate;
(3S)-3-[(2R)-2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy]-1-ethyl-1-(3-phenylsulphanylpropyl)pyrrolidinium trifluoroacetate;
(3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;
(3S)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;

(3R)-3-[(2S)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;

(3S)-3-[(2S)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;

(3R)-1-Methyl-1-phenethyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium bromide;

(3S)-1-Methyl-1-phenethyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium bromide;

(3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(3-hydroxyphenoxy)propyl]-1-methylpyrrolidinium formate;

(3R)-3-{[(9-hydroxy-9H-fluoren-9-yl)carbonyl]oxy}-1-methyl-1-(4-oxo-4-phenylbutyl)pyrrolidinium formate;

(3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(4-oxo-4-thien-2-ylbutyl)pyrrolidinium chloride;

(3R)-1-[4-(4-Fluorophenyl)-4-oxobutyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-methylpyrrolidinium formate;

(3R)-1-[3-(3-Cyanophenoxy)propyl]-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methylpyrrolidinium formate;

(3R)-3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methyl-1-[3-(naphthalen-1-yloxy)propyl]pyrrolidinium formate;

(3R)-3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methyl-1-[3-(methylphenylamino)propyl]pyrrolidinium chloride;

(3R)-1-[3-(Benzothiazol-2-yloxy)propyl]-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methylpyrrolidinium chloride;

(3R)-1-[3-(Biphenyl-4-yloxy)propyl]-3-[(2R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methylpyrrolidinium chloride;

(3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-[3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propyl]pyrrolidinium bromide;

(3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-[3-(1-methyl-1H-imidazol-2-ylsulfanyl)propyl]pyrrolidinium chloride;

(3R)-1-[3-(2-Chlorophenoxy)propyl]-3-[(2R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methylpyrrolidinium chloride;
3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-ethyl-1-[3-(4-methoxyphenoxy)propyl]pyrrolidinium bromide; and
(3R)-1-(2-Benzyloxyethyl)-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methylpyrrolidinium bromide.

20. (Currently amended) A compound according to claim 1 ~~which is one of~~chosen from:
(1*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-phenethylpyrrolidinium bromide (diastereomer 1);
(1*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-phenethylpyrrolidinium bromide (diastereomer 2);
(1*,3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide (diastereomer 1);
(1*,3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide (diastereomer 2);
(1*,3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide (diastereomer 1);
(1*,3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide (diastereomer 2);
(1*,3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide (diastereomer 1);
(1*,3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide (diastereomer 2);
(1*,3S)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide (diastereomer 1);
(1*,3S)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide (diastereomer 2);

(1*,3R)-1-Methyl-1-phenethyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium bromide (diastereomer 1);

(1*,3R)-1-Methyl-1-phenethyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium bromide (diastereomer 2);

(1*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenylallyl)pyrrolidinium bromide (diastereomer 1);

(1*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenylallyl)pyrrolidinium bromide (diastereomer 2);

(1*, 3R)-1-[4-(4-Fluorophenyl)-4-oxobutyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-methylpyrrolidinium chloride (diastereomer 1);

(1*,3S)-1-[3-(4-Fluorophenoxy)propyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-methylpyrrolidinium chloride (diastereomer 1);

(1*,3S)-1-[3-(4-Fluorophenoxy)propyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-methylpyrrolidinium chloride (diastereomer 2);

(1*, 3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenylpropyl)pyrrolidinium bromide (diastereomer 1);

(1*, 3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenylpropyl)pyrrolidinium bromide (diastereomer 2);

(1*,3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide (diastereomer 1);

(1*,3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide (diastereomer 2);

(1*, 3R)-1-[3-(Benzo[1,3]dioxol-5-yloxy)propyl]-1-methyl-3-[(9H-xanthen-9-ylcarbonyl)oxy]pyrrolidinium bromide (diastereomer 1);

(1*, 3R)-1-[3-(Benzo[1,3]dioxol-5-yloxy)propyl]-1-methyl-3-[(9H-xanthen-9-ylcarbonyl)oxy]pyrrolidinium bromide (diastereomer 2);

(1*, 3S)-1-Methyl-1-(3-o-tolyloxypropyl)-3-[(9H-xanthen-9-ylcarbonyl)oxy]pyrrolidinium bromide (diastereomer 1);

(1*, 3S)-1-Methyl-1-(3-o-tolyloxypropyl)-3-[(9H-xanthen-9-ylcarbonyl)oxy]pyrrolidinium bromide (diastereomer 2);

(1*, 3R)-1-[3-(Biphenyl-4-yloxy)propyl]-3-[(2R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methylpyrrolidinium chloride (diastereomer 1)~~,~~;
(1*, 3R)-1-[3-(Biphenyl-4-yloxy)propyl]-3-[(2R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methylpyrrolidinium chloride (diastereomer 2)~~,~~;
(1*, 3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-[3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propyl]pyrrolidinium bromide (diastereomer 1)~~,~~; and
(1*, 3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-[3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propyl]pyrrolidinium bromide (diastereomer 2).

21. (Currently amended) A process for producing a compound of formula (I), as ~~defined in any one of the preceding claims~~claimed in claim 1, ~~which process comprises~~comprising reacting an alkylating agent of formula R4-W with an intermediate of formula (II)~~.~~



(II)

wherein ~~m, n, A, B, D, R1, R2, R3 and R4 are as defined in claim 1 and~~ W is ~~any suitable~~ a leaving group.

22. (Currently amended) A process according to claim 21, wherein the compound of formula (II) is obtained by reaction of a compound of formula (V)



(V)

wherein ~~D is as defined in claim 1 and~~ L is a leaving group,
with a compound of formula (VI)



(VI)

~~wherein m, n, A, B, D, R1, R2 and R3 are as defined in claim 1~~.

23. (Currently amended) A compound ~~of formula (II), which is one of~~chosen from:
2-Hydroxy-2,2-dithien-2-ylacetic acid (3R)-1-(2-phenoxyethyl)pyrrolidin-3-yl ester;

2-Hydroxy-2,2-dithien-2-ylacetic acid (3R)-1-(3-phenoxypropyl)pyrrolidin-3-yl ester;

2-Hydroxy-2,2-dithien-2-ylacetic acid (3R)-1-(3-thien-2-ylpropyl)pyrrolidin-3-yl ester; and

2-Hydroxy-2,2-dithien-2-ylacetic acid (3R)-1- phenethylpyrrolidin-3-yl ester.

24. (Currently amended) A compound ~~of formula (VI), which is one of~~chosen from:
(3R)-1-(3-phenoxypropyl)pyrrolidin-3-ol and

(3R)-1-(3-thien-2-ylpropyl)pyrrolidin-3-ol.

25. (Currently amended) A process for producing a compound as claimed in claim 1, comprising ~~of formula (I), as defined in any one of the preceding claims, which process comprises~~

reacting an alkylating agent of formula (IV)



(IV)

wherein ~~m, n, A, B, D, R1, R2 and R3 is as defined in claim 1 and~~ W represents ~~any suitable~~a leaving group,
with an intermediate of formula (III)~~.~~



(III)

~~wherein R4 and D are as defined in claim 1~~.

26. (Currently amended) A pharmaceutical composition comprising a compound ~~according to any one of claims 1 to 20~~as claimed in claim 1 ~~in admixture with a~~ and at least one pharmaceutically acceptable carrier or diluent.

Claims 27-29 (Cancelled)

30. (Currently amended) A method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of M3 muscarinic

receptors, ~~which comprises~~comprising administering to said subject an effective amount of a compound as claimed in claim 1~~defined in any one of claims 1 to 20~~.

31. (Original) A method according to claim 30 wherein the pathological condition is a respiratory, urological or gastrointestinal disease or disorder.

32. (Currently amended) A ~~combination product~~ composition comprising
(i) a compound as claimed in claim 1 ~~according to any one of claims 1 to 20~~; and
(ii) ~~another~~ a compound effective in the ~~treament~~ treatment of a respiratory, urological or gastrointestinal disease or disorder

~~for simultaneous, separate or sequential use~~.

33. (Currently amended) A composition ~~combination product~~ according to claim 32 comprising
(i) a compound as claimed in claim 1~~according to any one of claims 1 to 20~~; and
(ii) ~~a~~ at least one compound chosen from: a β2 agonist, steroid, antiallergic drug, phosphodiesterase IV inhibitor and/~~or~~ a leukotriene D4 (LTD4) antagonist
~~for simultaneous, separate or sequential use in the treatment of a respiratory disease~~.

34. (New) A pharmaceutical composition according to claim 26, wherein the composition is an admixture.